vx-001
Vaccineexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Aug 1, 2012 (NCT01935154)
Timeline
2010s
- Jan 1, 2012
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Telomerase reverse transcriptaseImmunity, active
TERT immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- telomerase reverse transcriptase p572y, human
- tert(572y) peptide, human
- vx 001
- vx-001
- vx-001
- vx001 cpd
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01935154 | Phase 2 | Aug 1, 2012 | Iaso General Hospital, Athens, Vaxon Biotech |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Iaso General Hospital, Athens | Academic/Hospital | 1 | 0 | 1 | 2012 |
| Vaxon Biotech | For profit | 1 | 1 | 1 | 2012 |
2 organizations
Page 1 / 1